Clinical Scorecard: Hepatocellular Carcinoma in Pediatric and Adolescent Populations: Clinical Features and Management Strategies
At a Glance
Category
Detail
Condition
Hepatocellular carcinoma (HCC) in children and adolescents (≤20 years)
Key Mechanisms
HBV infection acquired perinatally or inherited metabolic disorders; presence of large tumors, portal vein tumor thrombus, and distant metastasis
Target Population
Children and adolescents aged ≤20 years diagnosed with HCC
Care Setting
Specialized hepatobiliary oncology centers with multidisciplinary management
Key Highlights
HCC in children and adolescents is rare (0.5–1%) but exhibits more malignant features than adult HCC.
HBV infection is highly prevalent (81.5%) in pediatric/adolescent HCC patients, especially in endemic regions like China.
Resection is the main curative treatment; the role of TACE remains controversial with limited evidence of survival benefit.
Guideline-Based Recommendations
Diagnosis
Diagnosis confirmed by histology or at least two imaging modalities combined with elevated alpha-fetoprotein (AFP) levels.
Tumor staging according to the 7th TNM system by UICC/AJCC.
Management
Surgical resection is the preferred curative treatment for eligible patients.
Transarterial chemoembolization (TACE) may be considered but has unclear survival benefits in pediatric/adolescent HCC.
Supportive treatment is associated with poorer survival outcomes.
Monitoring & Follow-up
Regular follow-up every 2–3 months in the first postoperative year, then every 3–6 months thereafter.
Monitoring includes clinical assessment, imaging, and AFP levels.
Risks
Advanced TNM stage, presence of portal vein tumor thrombus, distant metastasis, elevated total bilirubin and AST levels are associated with worse prognosis.
Uneven distribution of TNM stages influences treatment outcomes.
Patient & Prescribing Data
65 patients aged ≤20 years with HCC, predominantly male (52/65), median age 16.8 years, mostly HBV-infected (81.5%).
Initial treatment with resection significantly improves overall survival compared to supportive treatment; TACE shows some survival benefit over supportive care but less than resection.
Clinical Best Practices
Early identification and staging of HCC using imaging and AFP levels are critical for treatment planning.
Prioritize surgical resection in patients with early or moderate TNM stage for improved survival.
Consider TACE cautiously in patients with unresectable tumors, acknowledging limited evidence in pediatric/adolescent populations.
Monitor liver function tests (TBIL, AST) and tumor characteristics (portal vein thrombus, metastasis) to assess prognosis and guide management.
The Eugene M. & Christine E. Lynn Cancer Institute at Boca Raton Regional Hospital, part of Baptist Health, reached an important milestone in the advancement of cancer care with the successful treatment of its first patient utilizing proton therapy, according to physicians at both the Institute and the hospital.
